Clinical Trials Browser

Phase 1/2 × Active not recruiting × Drug Therapy × Clear all

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04888312 2025-10-08

OPTIMIZE-1

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04528680 2025-07-31

SC9/ABX

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT03544736 2023-03-22

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

Phase 1/2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms